Evaluation of potential interaction between vinorelbine and clarithromycin

Annals of Pharmacotherapy

Volumn 43, Issue 3, 2009, Pages 453-458

  Yano, Ryoichi ^a   Tani, Daisuke ^a   Watanabe, Kyohei ^a   Tsukamoto, Hitoshi ^a   Igarashi, Toshiaki ^a   Nakamura, Toshiaki ^a   Masada, Mikio ^a,b  

^a UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Clarithromycin; Drug drug interaction; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; CLARITHROMYCIN; GEFITINIB; GEMCITABINE; NAVELBINE; UFT;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLARITHROMYCIN; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEX CHARACTERISTICS; VINBLASTINE;

EID: 62949167207     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L432     Document Type: Article

References (35)

1. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group
2. Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63. DOI 10.1200/JCO.2006.06.1044
3. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-72.
4. Martin M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219-25. DOI 10.1016/S1470-2045(07)70041-4
5. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
6. The Elderly Lung Cancer Vinorelbine Italian Study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
7. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004;125(2 suppl):52S-61S. DOI 10.1378/chest.l 25.2-suppl.52S
8. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592-600.
9. Swinbanks D. Deaths bring clinical trials under scrutiny in Japan. Nature 1994:369:697. DOI 10.1038/369697b0
10. Watabe T. Strategic proposals for predicting drug-drug interactions during new drug development: based on sixteen deaths caused by interactions of the new antiviral sorivudine with fluorouracil prodrugs. J Toxicol Sci 1996;21:299-300.
11. Kanamitsu SI, Ito K, Okuda H, et al. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil. Drug Metab Dispos 2000;28:467-74.
12. Product information. Clarith (clarithromycin). Tokyo: Taisho Toyama Pharmaceutical Co., Ltd., September 2008.
13. Product information. Navelbine injection (vinorelbine tartrate). Tokyo: Kyowa Hakko Kirin Co., Ltd., October 2008.
14. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22. DOI 10.2174/ 138920008784220664
15. Horn JR, Hansten PD, Chan L-N. Proposal for new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. Epub 27 Mar 2007. DOI 10.1345/aph.lH423
16. Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E. Vinlastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol 1995;35:188-90. DOI 10.1007/BF00686546
17. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Disp 2000:28:1121-7.
18. Beulz-Riche D, Grude P, Sautel F, Filaquier C, Riche C, Ratanasavanh D. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 2005;19:545-53. DOI 10.1111/j.1472-8206. 2005.00367
19. Wong M, Balleine RL, Blair EYL, et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006;24:2448-55. DOI 10.1200/JCO.2005.02.1295
20. Adams DJ, Knick VC. P-glycoprotein mediated resistance to 5' -non-anhydro-vinblastine (Navelbine). Invest New Drug 1995;13:13-21. DOI 10.1007/BF02614215
21. Bóhme A, Gancer A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995;71:311-2. DOI 10.1007/BF01697985
22. Fedeli L, Colozza M, Boschetti E. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 1989;64:1805-11. DOI 10.1002/1097-0142(1989110I)64:9<1805::AID- CNCR2820640908> 3.0.CO;2-D
23. Bosque E. Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy (letter). Ann Intern Med 2001 ; 134:427.
24. Yoshimura M, Nakamura S, Imamura F, Ueno K, Yamamoto S, Igarashi T. Severe myelotoxicity in a combination of gefitinib and vinorelbine. Lung Cancer 2004;45:121-3. DOI 10.1016/j.lungcan.2004.01.006
25. Hung IFN, Wu AKL, Chen VCC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005;41:291-300. DOI 10.1086/431592
26. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001;35:26- 31. DOI 10.1345/aph.l0177
27. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000;34:495-513. DOI 10.1345/aph.l9138
28. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450 (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000;50:285-95. DOI 10.1046/j.1365-2125. 2000.00261
29. Larrey D, Tinel M, Pessayre D. Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem Pharmacol 1983: 32:1487-93. DOI 10.1016/0006-2952(83)90470-7
30. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989;250:746-51.
31. Wang L, Kitachi K, Hui CS, et al. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol 2000;27:587-93. DOI 10.1046/j. 1440-1681.2000.03308
32. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64:123-8. DOI 10.1016/S0009-9236(98)90030-3
33. Eberl S, Renner B, Neubert A. et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiologic studies. Clin Pharmacokinet 2007;46:1039-49.
34. Van Tellingen O, Buckle T, Jonker JW, van der Valk MA, Beijnen JH. Pglycoprotein and Mrpl collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br J Cancer 2003;89:1776-82. DOI 10.1038/sj.bjc.6601363
35. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003;42:107-21.